comparemela.com

Latest Breaking News On - Link therapeutics - Page 1 : comparemela.com

MediLink Therapeutics announces a multi-target TMALIN® ADC technology platform license agreement with BioNTech, expanding their global strategic partnership

SUZHOU, China, May 26, 2024 /PRNewswire/ MediLink Therapeutics Co., Ltd. , a clinical-stage biotech company, today announces a new strategic collaboration with BioNTech SE , a next-generation.

United statesPrnewswire medilink therapeutics suzhou co ltdLink therapeuticsMainland chinaHong kong special administrative regionMedilink therapeutics

MediLink Therapeutics Announces Worldwide Collaboration and License Agreement with Roche

MediLink Therapeutics ("MediLink"), announced today that it has entered into a worldwide collaboration and license agreement with Roche (SIX: RO, ROG; OTCQX: .

United statesRoche cicoIrvan ariyanaMedilink therapeutics suzhou co ltdChina innovation centerLink therapeuticsTumor microenvironment activableMedilink therapeutics

MediLink Therapeutics Announces Strategic Collaboration and Worldwide License Agreement with BioNTech to develop next-generation anti-cancer antibody-drug conjugate

/PRNewswire/ MediLink Therapeutics ("MediLink"), announced today that it has entered into a strategic research collaboration and worldwide license agreement.

United statesMedilink therapeuticsHuman epidermal growth factor receptorMainland chinaHong kong special administrative regionMacau special administrativeAntitrust improvementsLink therapeuticsTumor microenviroment activableMedilink therapeutics suzhou co

NEXT Oncology and MediLink Therapeutics Take Team Approach to Next Level on Phase 1 First in Human Clinical Trial in San Antonio | Region

SAN ANTONIO & CAMBRIDGE, Mass. (BUSINESS WIRE) Oct 9, 2023

United kingdomUnited statesAnthony tolcherSasha stannAlisa owensActivable linkerUs oncology networkLink therapeuticsHuman clinicalSouth texasSenior directorClinical operationsMedilink therapeuticsTumor microenvironment activableTexas oncologyBusiness wire

Latest Updates of Viva s Portfolio Companies

/PRNewswire/ Even with the ever-changing situation, technological innovation is still the most critical component for biopharmaceutical companies long-term.

United statesSan diegoViva bioinnovatorAlzheimer associationDrug administrationCapital medical universityTechnology commission of shanghai municipalityChina national medical products administrationQurebio ltdDepartment of defenseNational institute of neurological disordersInnovation fundAlzheimer drug discovery foundationAcelink therapeutics incRainwater charitable foundationHarrington discovery institute

vimarsana © 2020. All Rights Reserved.